Ex vivo expansion of human mesenchymal stem cells in defined serum-free media.
Ex vivo expansion of human mesenchymal stem cells in defined serum-free media.
复制标题
DOI：
10.1155/2012/123030
复制
发表时间：
2012
影响因子：
4.3
通讯作者：
Behie LA
中科院分区：
文献类型：
--
作者：
Jung S;Panchalingam KM;Rosenberg L;Behie LA
人类间充质干细胞（hMSC）目前正在评估其在临床研究中治疗各种疾病，病症和损伤的治疗潜力。迄今为止，早期研究表明，使用自体和同种异体hMSCs似乎是安全的;然而，在最近的后期临床试验中尚未证明疗效。优化的细胞生物处理方案可以增强hMSC治疗剂的功效以及安全性。用于产生hMSC的经典培养基通常补充有不明确的补充物，例如胎牛血清（FBS）或人源替代物。理想地，期望培养基具有良好定义的无血清制剂，其支持hMSC的有效生产，同时保持其治疗和分化能力。为了实现这一目标，我们在这里审查目前的细胞培养基的hMSCs和讨论媒体的发展战略。
Human mesenchymal stem cells (hMSCs) are presently being evaluated for their therapeutic potential in clinical studies to treat various diseases, disorders, and injuries. To date, early-phase studies have indicated that the use of both autologous and allogeneic hMSCs appear to be safe; however, efficacy has not been demonstrated in recent late-stage clinical trials. Optimized cell bioprocessing protocols may enhance the efficacy as well as safety of hMSC therapeutics. Classical media used for generating hMSCs are typically supplemented with ill-defined supplements such as fetal bovine serum (FBS) or human-sourced alternatives. Ideally, culture media are desired to have well-defined serum-free formulations that support the efficient production of hMSCs while maintaining their therapeutic and differentiation capacity. Towards this objective, we review here current cell culture media for hMSCs and discuss medium development strategies.
登录
查看更多内容
影响因子：
13.6
作者：
Ankrum J;Karp JM
通讯作者：
Karp JM
影响因子：
5.6
作者：
Doucet, C;Ernou, I;Lataillade, JJ
通讯作者：
Lataillade, JJ
DOI：
10.1073/pnas.1008117107
发表时间：
2010-08-03
影响因子：
11.1
作者：
Bartosh, Thomas J.;Ylostalo, Joni H.;Prockop, Darwin J.
通讯作者：
Prockop, Darwin J.
影响因子：
11.2
作者：
Bernardo, Maria Ester;Zaffaroni, Nadia;Locatelli, Franco
通讯作者：
Locatelli, Franco
影响因子：
20.3
作者：
Aggarwal, S;Pittenger, MF
通讯作者：
Pittenger, MF